Swiss Re AG · SIX:SREN
Swiss Re — Investor Presentation (October 2023)
9 slides from Swiss Re's investor presentation, October 2023
Slide 1: John Schoonbee, Global Chief Medical Officer, Swiss Re
John Schoonbee Global Chief Medical Officer Swiss Re
Slide 2: I want to put a ding in metabolic ill-health
Slide 3: Metabolic Health
Metabolic Health • Gerald Reaven 1988 • “metabolic syndrome” is therefore defined by insulin resistance 3
Slide 4: Insulin resistance is a root cause of many NCDs, not just CVD
Insulin resistance is a root cause of many NCDs, not just CVD → Metabolic health requires insulin sensitivity 4
Slide 5: Individual mortality impact modelled by Swiss Re
Individual mortality impact modelled by Swiss Re Basic Info Baseline (mean) Difference at 6 months Age 62 BMI 31.3 -2.4 Sex M Systolic BP 140 -11 Smoker NS Diastolic BP 81 -5 Term 20 Trigs 199 -66 Term left 20 TC/HDL 5.5 -1.1 Sum assured $ 1’000’000 HbA1c 7.5 -1.3 Expected Extra deaths Extra deaths
Slide 6: Contribution to Predicted Reduction to Death Claims
Contribution to Predicted Reduction to Death Claims Mortality claim reduction Death Claims Modelled to reduce by 13% 20% No reduction younger, much better No MetS or HI than average (39%) mortality 43% Other MetS,HI (38%) average age, above average mortality 13% reduction Pre-diabetics 25% 19% reduc
Slide 7: Event/condition risk difference (by insulin sensitivity in healthy adults)
Event/condition risk difference (by insulin sensitivity in “healthy” adults) • ~200 healthy adults, no DM, Hpt, CVD • median age 50 • f/u ~6 years • divided into tertiles of insulin sensitivity more less (resistance) sensitive sensitive • Diagnoses : – hypertension – cancer – coronary heart disease
Slide 8: Some logistics
Some logistics • Listen, learn, engage, consider your OWN bias • Timing • Social Media • A note about CGDs – insulin resistance (IR) requires hyperinsulinemia – hyperinsulinemia requires (excessive) hyperglycemia – hyperglycemia (frequency/extent) is a consequence of food – and therefore knowing wha
Slide 9: Slide 9